AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31162103 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage radiotherapy with short-term hormone therapy
Number of subjects: 0
Study 31162103 — intervention group
Group type: COMPARATOR
Intervention: Salvage radiotherapy without short-term hormone therapy
Number of subjects: 0
Study 29665130 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocktail of digoxin (0.25 mg), furosemide (1 mg), metformin (10 mg), and rosuvastatin (10 mg)
Number of subjects: 30
Study 29665130 — intervention group
Group type: COMPARATOR
Intervention: Single drug treatments (digoxin, furosemide, metformin, rosuvastatin)
Number of subjects: 30
Study 27178366 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (250 mg)
Number of subjects: 20
Study 27178366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 25100550 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth-supported service
Number of subjects: 63
Study 25100550 — intervention group
Group type: COMPARATOR
Intervention: Standard service
Number of subjects: 63
Study 22582680 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender aroma exposure (5 days)
Number of subjects: 15
Study 22582680 — intervention group
Group type: COMPARATOR
Intervention: Absence of lavender (control)
Number of subjects: 15
Study 20309531 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (21 mg)
Number of subjects: 48
Study 20309531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 18621987 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraluminal 70% ethanol/water
Number of subjects: 64
Study 18621987 — intervention group
Group type: COMPARATOR
Intervention: Heparinized saline
Number of subjects: 64
Study 16488641 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program combined with cognitive tasks (dual-task group, N=37)
Number of subjects: 68
Study 16488641 — intervention group
Group type: COMPARATOR
Intervention: Exercise program alone (single-task group, N=31)
Number of subjects: 68
Study 15022655 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey mixture (honey, beeswax, and olive oil)
Number of subjects: 39
Study 15022655 — intervention group
Group type: COMPARATOR
Intervention: Mixture C (honey mixture with corticosteroids in a 3:1 ratio)
Number of subjects: 39
Study 15022655 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey mixture
Number of subjects: 39
Study 11094673 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukoplast tape
Number of subjects: 0
Study 11094673 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleek tape
Number of subjects: 0
Study 11094673 — intervention group
Group type: EXPERIMENTAL
Intervention: Taping method (tape parallel to cannula axis and taping hub-giving set connection)
Number of subjects: 0
Study 11094673 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile adhesive dressings and tapes
Number of subjects: 0
Study 8756050 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 500 mg quinine base
Number of subjects: 18
Study 8756050 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of 500 mg quinine base
Number of subjects: 18
Study 1562344 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 66
Study 1562344 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 66
Study 3902482 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 30
Study 3902482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31033161 — intervention group
Group type: EXPERIMENTAL
Intervention: SC 1,3‐butanediol extract
Number of subjects: 30
Study 31033161 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no extract)
Number of subjects: 30
Study 31033161 — intervention group
Group type: COMPARATOR
Intervention: Positive control (kojic acid)
Number of subjects: 30
Study 27848021 — intervention group
Group type: EXPERIMENTAL
Intervention: Active (estim + swallow exercise)
Number of subjects: 170
Study 27848021 — intervention group
Group type: COMPARATOR
Intervention: Sham (sham estim + swallowing exercise)
Number of subjects: 170
Study 27848021 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients pooled together
Number of subjects: 170
Study 26049126 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT), 4 sessions
Number of subjects: 31
Study 26049126 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 31
Study 24075759 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (100,000 units oral)
Number of subjects: 50
Study 24075759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 21709591 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 1237
Study 21709591 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 1237
Study 21709591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1237
Study 19071997 — intervention group
Group type: EXPERIMENTAL
Intervention: Causal Inference in Randomized Experiments
Number of subjects: 0
Study 19071997 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-model translation (CMT) approach
Number of subjects: 0
Study 16501039 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 30
Study 15031570 — intervention group
Group type: EXPERIMENTAL
Intervention: BiPAP plus standard therapy (group 1)
Number of subjects: 30
Study 15031570 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy alone (group 2)
Number of subjects: 30
Study 11226986 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Doppler sonography (PDS) of the hilar renal artery
Number of subjects: 80
Study 9315764 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory Blood Pressure (ABP) measurement
Number of subjects: 419
Study 9315764 — intervention group
Group type: COMPARATOR
Intervention: Conventional Blood Pressure (CBP) measurement
Number of subjects: 419
Study 7693793 — intervention group
Group type: EXPERIMENTAL
Intervention: Single transfusion of the partner's lymphocytes in the third week of pregnancy
Number of subjects: 22
Study 7693793 — intervention group
Group type: COMPARATOR
Intervention: One to three transfusions of the partner's lymphocytes before the pregnancy started
Number of subjects: 22
Study 7693793 — intervention group
Group type: COMPARATOR
Intervention: Pre-conceptual transfusions
Number of subjects: 22
Study 3710290 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (PK 10169)
Number of subjects: 8
Study 3710290 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 8
Study 28318309 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostering Healthy Futures program (9‐month mentoring and skills group preventive intervention)
Number of subjects: 156
Study 28318309 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostering Healthy Futures program
Number of subjects: 156
Study 28318309 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 156
Study 29456149 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal Medication Schedule (UMS)
Number of subjects: 76
Study 29456149 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 76
Study 27177605 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and velpatasvir for 12 weeks
Number of subjects: 1
Study 24077325 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytochrome c levels at least the mean peak level
Number of subjects: 160
Study 24077325 — intervention group
Group type: COMPARATOR
Intervention: Cytochrome c levels below the mean peak level
Number of subjects: 160
Study 21975419 — intervention group
Group type: EXPERIMENTAL
Intervention: Elliptical exercise intervention, 15 sessions of supervised exercise
Number of subjects: 24
Study 21975419 — intervention group
Group type: EXPERIMENTAL
Intervention: Elliptical exercise intervention
Number of subjects: 24
Study 20818888 — intervention group
Group type: EXPERIMENTAL
Intervention: Icatibant (30 mg subcutaneously)
Number of subjects: 130
Study 20818888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 20818888 — intervention group
Group type: COMPARATOR
Intervention: Tranexamic acid (3 g daily for 2 days)
Number of subjects: 130
Study 17472802 — intervention group
Group type: EXPERIMENTAL
Intervention: New treatment options for ARMD
Number of subjects: 0
Study 17472802 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials
Number of subjects: 0
Study 17472802 — intervention group
Group type: EXPERIMENTAL
Intervention: Endpoints of clinical studies
Number of subjects: 0
Study 16120062 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.375 mg triazolam
Number of subjects: 13
Study 16120062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 12392589 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva nicotine concentration
Number of subjects: 13
Study 12392589 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma nicotine concentration
Number of subjects: 13
Study 12392589 — intervention group
Group type: COMPARATOR
Intervention: Saliva and plasma nicotine concentrations
Number of subjects: 13
Study 9987093 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (1 microgram/kg/min for over 15 min)
Number of subjects: 12
Study 9987093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7572826 — intervention group
Group type: EXPERIMENTAL
Intervention: JOBS II intervention for unemployed workers
Number of subjects: 1801
Study 2279256 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine 200 mg b.i.d.
Number of subjects: 60
Study 2279256 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin (open titrated)
Number of subjects: 60
Study 2279256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 368088 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol (180 to 480 mg daily)
Number of subjects: 20
Study 368088 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (180 to 480 mg daily)
Number of subjects: 20
Study 31018690 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity trainer
Number of subjects: 34
Study 31018690 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fidelity trainer
Number of subjects: 34
Study 31018690 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained cohort (high-fidelity and low-fidelity combined)
Number of subjects: 34
Study 31018690 — intervention group
Group type: COMPARATOR
Intervention: Control (no simulator exposure)
Number of subjects: 34
Study 30036571 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim 5 µg/kg/day i.v. from day 7 post-transplant until neutrophil recovery
Number of subjects: 145
Study 30036571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 30036571 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim
Number of subjects: 145
Study 27486672 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ear acupuncture points identified in infants with NAS
Number of subjects: 30
Study 27486672 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychovegetative rim identified as the most common active somatic area
Number of subjects: 30
Study 24762094 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 0
Study 24762094 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 2.0 mg
Number of subjects: 0
Study 24762094 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin (100 mg)
Number of subjects: 0
Study 24762094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22371876 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based counseling using a motivational interviewing framework (n = 1046)
Number of subjects: 2087
Study 22371876 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving mailed educational materials (n = 1041)
Number of subjects: 2087
Study 19460067 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0
Study 19460067 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0
Study 19460067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17568965 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to alcohol advertising around schools in sixth grade
Number of subjects: 2586
Study 17568965 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonusers of alcohol in sixth grade
Number of subjects: 2586
Study 15365963 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemofiltration (HF)
Number of subjects: 39
Study 15365963 — intervention group
Group type: COMPARATOR
Intervention: Hemodiafiltration (HDF)
Number of subjects: 39
Study 11880966 — intervention group
Group type: EXPERIMENTAL
Intervention: d4T-NVP-RTV
Number of subjects: 181
Study 11880966 — intervention group
Group type: EXPERIMENTAL
Intervention: d4T-NVP-NFV
Number of subjects: 181
Study 11880966 — intervention group
Group type: EXPERIMENTAL
Intervention: d4T-3TC-NFV (3 times daily)
Number of subjects: 181
Study 11880966 — intervention group
Group type: EXPERIMENTAL
Intervention: d4T-3TC-NVP-NFV
Number of subjects: 181
Study 10452470 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B lipid emulsion (1.0 mg/kg per day)
Number of subjects: 0
Study 10452470 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B dextrose (0.5 mg/kg per day)
Number of subjects: 0
Study 7872342 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI (enalapril or lisinopril)
Number of subjects: 31
Study 2222130 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% per week taper of short half-life benzodiazepines
Number of subjects: 63
Study 2222130 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% per week taper of long half-life benzodiazepines
Number of subjects: 63
Study 410133 — intervention group
Group type: EXPERIMENTAL
Intervention: T-suction drainage tubes placed in the vaginal vaults during operation
Number of subjects: 100
Study 410133 — intervention group
Group type: COMPARATOR
Intervention: Control group (no T-suction drainage)
Number of subjects: 100
Study 30611640 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.05 mg/kg
Number of subjects: 185
Study 30611640 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 5 mg
Number of subjects: 185
Study 30611640 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenous distilled water)
Number of subjects: 185
Study 29289941 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (5-day course)
Number of subjects: 1400
Study 29289941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1400
Study 26130355 — intervention group
Group type: EXPERIMENTAL
Intervention: Bracing
Number of subjects: 68
Study 26130355 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 68
Study 23863909 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 doses of GAD-alum (4D)
Number of subjects: 148
Study 23863909 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of GAD-alum (2D)
Number of subjects: 148
Study 23863909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 21747340 — intervention group
Group type: EXPERIMENTAL
Intervention: Partogram
Number of subjects: 7827
Study 21747340 — intervention group
Group type: EXPERIMENTAL
Intervention: Partogram with defined management protocols
Number of subjects: 7827
Study 21747340 — intervention group
Group type: COMPARATOR
Intervention: Partogram versus no partogram
Number of subjects: 7827
Study 21747340 — intervention group
Group type: EXPERIMENTAL
Intervention: Partogram with two-hour action line
Number of subjects: 7827
Study 21747340 — intervention group
Group type: EXPERIMENTAL
Intervention: Partogram with three-hour action line
Number of subjects: 7827
Study 21747340 — intervention group
Group type: EXPERIMENTAL
Intervention: Partogram with alert line
Number of subjects: 7827
Study 21747340 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier intervention
Number of subjects: 7827
Study 19343928 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealapex (group B)
Number of subjects: 40
Study 19343928 — intervention group
Group type: EXPERIMENTAL
Intervention: NaOCl/Sealapex (group C)
Number of subjects: 40
Study 19343928 — intervention group
Group type: EXPERIMENTAL
Intervention: EDTA/NaOCl/Sealapex (group D)
Number of subjects: 40
Study 19343928 — intervention group
Group type: EXPERIMENTAL
Intervention: Etch-and-rinse (Single Bond) and self‐etching (Clearfil SE Bond) adhesives
Number of subjects: 40
Study 19343928 — intervention group
Group type: COMPARATOR
Intervention: Control group (group A)
Number of subjects: 40
Study 19343928 — intervention group
Group type: EXPERIMENTAL
Intervention: EDTA followed by NaOCl treatment
Number of subjects: 40
Study 17082991 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 19
Study 15571006 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin
Number of subjects: 177
Study 15571006 — intervention group
Group type: COMPARATOR
Intervention: Multivitamin supplements
Number of subjects: 177
Study 15037686 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal sumatriptan (10 mg for 20-39 kg; 20 mg for >40 kg)
Number of subjects: 94
Study 15037686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 10460981 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot reflexology at zones corresponding to the right kidney
Number of subjects: 32
Study 10460981 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment on other foot zones
Number of subjects: 32
Study 7567488 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiocclusive hydroactive wound dressing
Number of subjects: 250
Study 7567488 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusive hydrocolloid dressing
Number of subjects: 250
Study 7567488 — intervention group
Group type: COMPARATOR
Intervention: Conventional absorbent dressing
Number of subjects: 250
Study 2329393 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine oral rinse used as a preoperative rinse and immediate postextraction irrigant
Number of subjects: 0
Study 2329393 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% cetylpyridium used as a preoperative rinse and postextraction saline irrigation
Number of subjects: 0
Study 2329393 — intervention group
Group type: COMPARATOR
Intervention: Postextraction irrigation with normal saline
Number of subjects: 0
Study 7247088 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous epinephrine combined with aerosol placebo
Number of subjects: 25
Study 7247088 — intervention group
Group type: COMPARATOR
Intervention: Aerosol epinephrine with injected placebo
Number of subjects: 25
Study 31961854 — intervention group
Group type: EXPERIMENTAL
Intervention: OFC (orbitofrontal cortex)
Number of subjects: 0
Study 31961854 — intervention group
Group type: EXPERIMENTAL
Intervention: OFC (orbitofrontal cortex) and HPC (hippocampus)
Number of subjects: 0
Study 31961854 — intervention group
Group type: EXPERIMENTAL
Intervention: HPC-OFC connectivity
Number of subjects: 0
Study 30396317 — intervention group
Group type: EXPERIMENTAL
Intervention: QIV-GC3110A
Number of subjects: 1299
Study 30396317 — intervention group
Group type: COMPARATOR
Intervention: TIV-Yamagata
Number of subjects: 1299
Study 30396317 — intervention group
Group type: COMPARATOR
Intervention: TIV-Victoria
Number of subjects: 1299
Study 26869148 — intervention group
Group type: EXPERIMENTAL
Intervention: l-theanine (200 mg)
Number of subjects: 20
Study 26869148 — intervention group
Group type: EXPERIMENTAL
Intervention: caffeine (160 mg)
Number of subjects: 20
Study 26869148 — intervention group
Group type: EXPERIMENTAL
Intervention: theanine-caffeine combination
Number of subjects: 20
Study 26869148 — intervention group
Group type: COMPARATOR
Intervention: black tea (one cup)
Number of subjects: 20
Study 26869148 — intervention group
Group type: COMPARATOR
Intervention: placebo (distilled water)
Number of subjects: 20
Study 25302852 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide-prednisone
Number of subjects: 332
Study 25302852 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 332
Study 23727083 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 83
Study 23727083 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg
Number of subjects: 83
Study 23727083 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 80 mg vs Atorvastatin 10 mg
Number of subjects: 83
Study 21856001 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg intravenous ramosetron (group A)
Number of subjects: 124
Study 21856001 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg oral ramosetron (group B)
Number of subjects: 124
Study 21856001 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 0.1 mg oral and 0.3 mg intravenous ramosetron (group C)
Number of subjects: 124
Study 19074686 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror Therapy (MT)
Number of subjects: 36
Study 19074686 — intervention group
Group type: COMPARATOR
Intervention: Control Therapy (CT)
Number of subjects: 36
Study 17920916 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan and prednisone plus thalidomide (MPT; n=125)
Number of subjects: 447
Study 17920916 — intervention group
Group type: COMPARATOR
Intervention: Melphalan and prednisone (MP; n=196)
Number of subjects: 447
Study 17920916 — intervention group
Group type: COMPARATOR
Intervention: Reduced-intensity stem cell transplantation using melphalan 100 mg/m2 (MEL100; n=126)
Number of subjects: 447
Study 15277909 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.2 mg orally and as a patch) administered the night before surgery and on the morning of surgery
Number of subjects: 190
Study 11504278 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg (Days 1-7) and 400 mg (Days 8-28)
Number of subjects: 32
Study 11504278 — intervention group
Group type: COMPARATOR
Intervention: Modafinil 200 mg and 400 mg + Methylphenidate 20 mg (Days 22-28)
Number of subjects: 32
Study 9692692 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 6 mg daily
Number of subjects: 75
Study 9692692 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 3 mg daily
Number of subjects: 75
Study 9692692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 8160597 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardiac defibrillator
Number of subjects: 1000